常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.53/-4.26
|
|
企業價值
606.32M
|
| 資產負債 |
|
每股賬面淨值
6.46
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
37.00K
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/15 21:09 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |

10.79 
